Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lucie Ellis

Lucie Ellis, based in the UK, joined the SCRIP Intelligence team in 2012. In her current position as a Creative Content Reporter, she is focused on introducing innovative and imaginative ways to display content on the web and routinely annoys SCRIP’s technology and design teams by thinking too far outside of the box. As a reporter covering the pharma and biotech world, Lucie understandably spends a lot of her time writing about drugs and money or Googling abbreviations. However she has a particular interest in employment trends, social and digital media use by industry, patient-centricity, big data, and clinical research in the metabolic and CNS fields. Lucie enjoys traveling and can often be seen out and about at industry events across the globe as SCRIP’s roving reporter.
Set Alert for Articles By Lucie Ellis

Latest From Lucie Ellis

Gates Foundation’s $40m Incentivizes Cancer Specialist Immunocore To Develop TB, HIV Drugs

Oxford, UK-based Immunocore, which is developing immunotherapies against cancer, has secured $40m in funding from the Bill & Melinda Gates Foundation to boost its research activities in infectious diseases. The company hopes to develop novel therapeutics to reduce treatment timelines and improve outcomes for patients with HIV and TB.

Deals Infectious Diseases

GSK's COPD Triple Combo Wins EU Nod

Ahead of a regulatory verdict in the US, GSK's triple combination therapy for COPD, Trelegy Ellipta, has won a positive recommendation in Europe.

Approvals Respiratory

Prima BioMed Carves A Niche In Busy IO Pipeline

Emerging Company Profile: Prima BioMed, a biotech developing immuno-oncology medicines, has been patiently waiting in the wings. Now, with three of its LAG-3 drug candidates partnered with pharma players, the company is ready to take center stage.

StartUps and SMEs ImmunoOncology

2017 Filing For Shionogi's Novel Flu Drug In Japan On Back Of Strong Phase III Data

Shionogi is on track to file its novel flu treatment S-033188 with regulators in Japan by the end of the year on the back of positive Phase III data.

Clinical Trials Research and Development Strategies

GSK's COPD Triple Combo To Challenge Chiesi's Trimbow In EU

GSK's closed triple combination for COPD, Trelegy, is expected to get a green light for approval in Europe on Friday – but the product will be fighting for market share against Chiesi's triple combination Trimbow, which has a head start.

Approvals Regulation

Lilly's Abemaciclib On Par With Ibrance In Breast Cancer, But Not 'Clearly Superior'

Despite returning positive results in the MONARCH-3 trial, Lilly's breast cancer therapy abemaciclib has sparked mixed reactions at ESMO; the big pharma will need to work on differentiating the drug from other CDK 4/6 therapies.

Clinical Trials Cancer
See All